Supernus Pharmaceuticals reported a strong first quarter in 2022, with a 16% increase in total revenues to $152.5 million compared to Q1 2021. Net earnings and diluted earnings per share (GAAP) were $25.6 million and $0.43, respectively. The FDA approved Qelbree for ADHD treatment in adults, and Qelbree prescriptions increased by 38% compared to Q4 2021.
Total revenues for Q1 2022 reached $152.5 million, a 16% increase year-over-year.
Net earnings for Q1 2022 were $25.6 million, with a diluted EPS of $0.43.
Qelbree prescriptions continued to grow, reaching 47,324 in Q1 2022, a 38% increase compared to Q4 2021.
The FDA approved Qelbree for the treatment of ADHD in adults.
Supernus Pharmaceuticals reiterates its full-year 2022 financial guidance, with total revenues expected to be between $640 million and $680 million and operating earnings between $20 million and $40 million.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance